SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility as traders balance technical momentum against geopolitical uncertainty surrounding regional conflicts and pending diplomatic negotiations. Community sentiment remains sharply divided, with bulls pointing to robust institutional inflows and long-term scarcity as catalysts for a squeeze, while bears highlight risks from potential regulatory shifts and macroeconomic pressures.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is surging as traders grow optimistic about progress on the Clarity Act, fueling speculation that clearer regulatory guidelines will catalyze institutional adoption and expand the company's role as a leading digital asset exchange. The community is actively debating the stock's correlation with Bitcoin's recent price action, with many using the current volatility to position themselves for a potential breakout toward prior resistance levels.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is currently at the center of a massive, retail-driven short squeeze, with the stock price skyrocketing as traders speculate that a supply-demand imbalance has trapped short sellers. The community is deeply divided between bulls celebrating an epic squeeze and bears warning of an inevitable, violent collapse fueled by high volatility and extreme option premiums.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and intense social media debate as investors weigh the company's aggressive and ongoing Bitcoin accumulation strategy against concerns regarding debt-funded dilution. Market participants are closely watching the stock's role as a levered proxy for Bitcoin, with sentiment split between those anticipating a major breakout tied to BTC price appreciation and others warning of unsustainable leverage and potential downside risks.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is attracting attention as investors anticipate upcoming data presentations at the American Urological Association conference and potential progress toward a BLA submission. The community is actively debating the company's valuation gap compared to sector peers and monitoring technical breakout levels, while some long-term shareholders remain focused on the clinical potential of CAN-2409 to address unmet needs in prostate cancer.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics is surging following the release of positive registrational trial data for its CAR T-cell therapy, miv-cel, in treating Stiff Person Syndrome, with the company announcing plans for a BLA submission in early 2026. The community is buzzing over the therapy's potential as a 'first-in-class' treatment for autoimmune diseases, fueling speculation regarding a potential buyout or partnership given the firm's robust clinical results and large-scale manufacturing advancements.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch (IMG) is gaining traction as community members highlight its passive Solana reward mechanism, which distributes earnings every six hours without requiring traditional staking. Supporters are framing the asset as a resilient, "battle-tested" play, focusing on long-term project building and a deflationary model that remains a key point of discussion for those looking to capitalize on automated on-chain rewards.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is currently attracting attention as a leveraged Bitcoin play, with investors closely watching the company's significant BTC holdings and the potential impact of its new digital credit ETF. The community is actively debating the company's long-term valuation and management strategies, balancing bullish sentiment regarding Bitcoin's future against concerns over past equity dilution and share performance.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors aggressively buy the dip, fueled by bullish analyst price target upgrades and speculation that the stock is poised to challenge new record highs despite its rapid recent run. The community is deeply divided between those betting on an inevitable breakout toward higher price levels driven by institutional demand, and skeptical traders highlighting the stock's overbought technical status and potential for a sharp pullback.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospace is currently trending as investors weigh strong earnings beats and a record-breaking $190 billion backlog against concerns regarding a conservative forward outlook and macroeconomic uncertainty. While the community is actively debating whether the recent share price pullback represents a tactical buying opportunity or a signal of cooling momentum, many continue to emphasize the firm's dominant position in the global aircraft engine market.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Nasdaq 100 futures edged up 0.68%, S&amp;P 500 futures were up 0.53%, and Dow Jones futures edged 0.47% higher.&nbsp;</li><li>Meanwhile, the S&amp;P 500, the Dow Jones Industrial Average, and the Nasdaq Composite all declined about 0.6% at close.&nbsp;</li><li>Asian markets were mixed in Wednesday’s opening trade, with the KOSPI and Nikkei 225 lower, while the Shanghai Composite opened in the green.</li></ul><p>U.S. stock futures inched higher in Tuesday’s overnight trading as markets priced in President Donald Trump’s announcement of a ceasefire extension with Iran, shortly before the deadline was set to expire on Wednesday.</p><p>As of 8:37 p.m. ET, Nasdaq 100 futures edged up 0.68%, S&amp;P 500 futures were up 0.53%, and Dow Jones futures edged 0.47% higher.</p><p>Meanwhile, ETFs tracking the benchmark indexes — the <a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), <a href="https://stocktwits.com/symbol/qqq">Invesco QQQ Trust</a> (QQQ) and <a href="https://stocktwits.com/symbol/dia">SPDR Dow Jones Industrial Average ETF</a> Trust (DIA) — also climbed higher late Tuesday, with retail sentiment in the green for all at the time of writing.</p><h2 class="st-heading-2">How Did US Markets Fare On Monday?</h2><p>The S&amp;P 500, the Dow Jones Industrial Average, and the Nasdaq Composite all declined about 0.6% at close over ongoing uncertainty about the peace negotiations.</p><figure class="table"><table><tbody><tr><td>Index</td><td>Move</td><td>Close</td></tr><tr><td>Dow Jones Industrial Average</td><td>0.59%</td><td>49,149.38</td></tr><tr><td>S&amp;P 500</td><td>0.63%</td><td>7,064.01</td></tr><tr><td>Nasdaq Composite</td><td>0.59%</td><td>24,259.96</td></tr></tbody></table></figure><h2 class="st-heading-2">US Market Drivers</h2><p>Investor sentiment was largely driven by the outcome of the U.S.-Iran peace talks. Stock futures in the U.S. ticked higher after-hours following President Donald Trump’s announcement of an extended ceasefire with Iran. However, the president said that despite the extension, military blockade in the Strait would continue.</p><p>"Based on the fact that the Government of Iran is seriously fractured, not unexpectedly so and, upon the request of Field Marshal Asim Munir, and Prime Minister Shehbaz Sharif, of Pakistan, we have been asked to hold our Attack on the Country of Iran until such time as their leaders and representatives can come up with a unified proposal," Trump said in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/116444507618729432">post</a> on Truth Social.</p><p>"I have therefore directed our Military to continue the Blockade and, in all other respects, remain ready and able, and will therefore extend the Ceasefire until such time as their proposal is submitted, and discussions are concluded, one way or the other,” he added.</p><p>Meanwhile, Iran has reportedly said that it won’t attend the talks with the U.S., calling it a “waste of time.” Previously, Iran <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/iran_un/status/2046671553572814980?s=46">asked</a> the United Nations to intervene in the matter related to the seizure of one of its vessels in the Strait of Hormuz, calling the move by the U.S. "a clear and material breach" of the ceasefire between the nations, while also demanding that the U.S. release the vessel, the crew, and the families captured aboard.</p><h2 class="st-heading-2">Trending Stocks To Watch</h2><p><strong>Poet Technologies (POET): </strong>Shares of the company surged on Tuesday, climbing higher in after-hours trading following CFO Thomas Mika’s dismissal of short-seller Wolfpack’s report on its status as a Passive Foreign Investment Company in an <a href="https://stocktwits.com/news-articles/markets/equity/poet-cfo-confirms-orders-from-marvell-waiting-on-foxconn-luxshare/cZBINvkRI65">exclusive interview with Stocktwits</a>. Mika also confirmed orders with Marvell Technology (MRVL).</p><p><strong>Navitas Semiconductor (NVTS): </strong>Shares of the specialized chip company gained more than 2% in overnight trading, after closing up 16% on optimism over the <a href="https://stocktwits.com/news-articles/markets/equity/why-is-nvts-stock-surging-today/cZBIYdZRI6B">appointment of Gregory M. Fischer</a>, a former Broadcom VP, as an independent director.</p><p><strong>Kyverna Therapeutics (KYTX): </strong>The clinical-stage biopharma company rallied over 29% in Tuesday’s overnight session after it said that its experimental one-time cell therapy <a href="https://stocktwits.com/news-articles/markets/equity/kytx-stock-soars-after-hours-whats-driving-the-rally/cZBB4WaRI6F">delivered solid results</a> in a trial.</p><p><strong>Tesla (TSLA): </strong>Elon Musk’s car maker is on the retail radar ahead of its <a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-premarket-ross-gerber-brand-backlash-ai-pivot-earnings-check/cZBIOqKRICO">first quarter earnings results</a> due in Wednesday’s after-market hours. Analysts expect the company to post revenue of $22.39 billion for the quarter, a growth of about 16% from the same period last year. &nbsp;&nbsp;&nbsp;&nbsp;</p><h2 class="st-heading-2">Broader Market Trends</h2><p>Meanwhile, oil futures fluctuated in Tuesday’s overnight trading, trending lower at the time of writing. WTI crude futures expiring in May were down about 0.07% to $89.61 a barrel, and Brent crude futures expiring in June were down about 0.02% to $98.46 a barrel.</p><p>Meanwhile, treasury yields on the benchmark 10-year were at 4.288% at 8.32 PM ET, while gold traded around $4,744.09 an ounce after climbing about 0.7%.</p><p>Asian markets were mixed in Wednesday’s opening trade, with the KOSPI and Nikkei 225 lower, while the Shanghai Composite opened in the green. Australian stocks also dipped lower at the open on Wednesday.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

08 April 2025, Hesse, Frankfurt/Main: The bronze figures of the bull (r) and bear, symbols of the upswing and downswing on the stock market, stand on the square in front of the stock exchange.  

Dow, Nasdaq, S&P 500 Futures Edge Higher After Trump Extends Iran Ceasefire: POET, NVTS, KYTX, TSLA Stocks Garner Focus Today

U.S. President Donald Trump said in a Truth Social post late Tuesday that he had extended the ceasefire with Iran, although adding that the military blockade in the Strait of Hormuz would continue. 

Equity

<ul class="summary-bullets"><li>The trial results were presented in a late-breaking oral session at the American Academy of Neurology (AAN) Annual Meeting in Chicago.</li><li>At 16 weeks, mobility improved significantly with eighty-one percent of patients achieving a clinically meaningful improvement, the company said.&nbsp;</li><li>Kyverna said the data support its plan to submit a biologics license application (BLA) to the FDA for miv-cel in SPS.</li></ul><p>Shares of Kyverna Therapeutics, Inc. (KYTX) jumped 24% after hours on Tuesday after the company said that its experimental one-time CAR-T cell therapy delivered rapid, lasting improvements in mobility and reversed disability in patients with stiff person syndrome (SPS) in a trial.</p><p>The results were presented in a late-breaking oral session at the American Academy of Neurology (AAN) Annual Meeting in Chicago.</p><h2 class="st-heading-2">Trial Results</h2><p>In the phase-2 trial, 26 patients who had not responded well to standard off-label therapies received a single dose of Kyverna’s miv-cel.</p><p>At 16 weeks, mobility improved significantly; eighty-one percent of patients achieved a clinically meaningful improvement. Two-thirds of those who needed walking aids at the start no longer required them. All 26 patients were able to stop chronic immunotherapies entirely, the company said. Disability, muscle stiffness, and sensitivity to spasms also improved markedly, it added.</p><p>Miv-cel was generally well-tolerated. The most common side effect was a temporary drop in neutrophil cell counts that was manageable, Kyverna said.</p><h2 class="st-heading-2">What Next?</h2><p>Kyverna said the data support its plan to submit a biologics license application (BLA) to the FDA for miv-cel in SPS. If approved, it would become the first approved treatment for the condition and the first CAR-T therapy approved for any autoimmune disease.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around KYTX stayed within the ‘extremely bullish’ territory over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’ levels.</p><p>A Stocktwits user expressed optimism for the company, highlighting the past experiences of its CEO Warner Biddle who previously worked with Kite Pharma. Kite was bought out by Gilead Sciences for $11.9 billion in 2017.</p><p><stembedurl>https://www.stocktwits.com/beststock/message/650960443</stembedurl></p><p>Another opined that miv-cel has a total addressable market of over $80 billion if its approved across multiple indications.</p><p><stembedurl>https://www.stocktwits.com/leon_dedrick/message/650960360</stembedurl></p><p><a href="https://stocktwits.com/symbol/KYTX">KYTX stock</a> has gained 11% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nio-gives-its-model-nemesis-lidar-vision-wallet-friendly-price-tag-unchanged/cZBIxJ6RI6N">NIO Gives Its Model Y Nemesis LiDAR Vision — Wallet-Friendly Price Tag Unchanged</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Rising stock market chart on a trading board background.

KYTX Stock Soars After Hours: What’s Driving The Rally? 

Kyverna reported strong pivotal trial results for its one-time CAR-T therapy miv-cel, showing rapid mobility improvements and reversal of disability in patients with stiff person syndrome.

Kyverna Therapeutics (NASDAQ:KYTX) Shares Down 7.2% - Should You Sell?

Kyverna Therapeutics (NASDAQ:KYTX) Trading Down 7.2% - What's Next...

Kyverna Therapeutics (NASDAQ:KYTX) Trading 6.2% Higher - Should You Buy?

Kyverna Therapeutics (NASDAQ:KYTX) Shares Up 6.2% - Still a Buy...

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of "Moderate Buy" from Analysts

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five analysts that are currently covering the stock, Marketbeat reports...

Kyverna Therapeutics (NASDAQ:KYTX)  Shares Down 6.7%   - Here's What Happened

Kyverna Therapeutics (NASDAQ:KYTX) Trading Down 6.7% - What's Next...

HC Wainwright Analysts Increase Earnings Estimates for KYTX

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Kyverna Therapeutics in a research report issued to clients and...

Brokers Issue Forecasts for KYTX FY2027 Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Stock analysts at HC Wainwright issued their FY2027 EPS estimates for shares of Kyverna Therapeutics in a research note issued on Monday, March 30th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings per share of...

Kyverna Therapeutics (NASDAQ:KYTX) Announces Earnings Results

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) posted its earnings results on Thursday. The company reported ($0.80) earnings per share (EPS) for the quarter, meeting the consensus estimate of...

Kyverna Therapeutics (KYTX) Expected to Announce Quarterly Earnings on Wednesday

Kyverna Therapeutics (NASDAQ:KYTX) will be releasing its Q4 2025 earnings before the market opens on Wednesday, April 1. (View Earnings Report at...

Max long

Hedged

Net short

All cash

Stocktwits

Stocktwits Polls

Investors are heavily buzzing about potential multi-billion dollar acquisition targets as Big Pharma looks to snap up CAR-T platforms.

The stock is reacting sharply to impressive 52-week clinical data and anticipation surrounding upcoming late-breaking trial results.

Traders are closely watching for potential secondary offerings as a common post-data trend in the biotech sector.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.75	--	--	N/A
Q4 '25	-$0.85	-$0.80	5.99%	BEAT
Q3 '25	-$0.97	-$0.85	12.47%	BEAT
Q2 '25	-$1.04	-$0.97	7.08%	BEAT
Q1 '25	-$1.13	-$1.03	8.50%	BEAT

KYTX
Kyverna Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest KYTX News

KYTXKyverna Therapeutics Inc.